Parkside Financial Bank & Trust Invests $27,000 in Fractyl Health, Inc. (NASDAQ:GUTS)

Parkside Financial Bank & Trust acquired a new stake in Fractyl Health, Inc. (NASDAQ:GUTS) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 13,333 shares of the company’s stock, valued at approximately $27,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in shares of Fractyl Health in the 3rd quarter valued at $25,000. JPMorgan Chase & Co. lifted its stake in Fractyl Health by 335.4% in the third quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock valued at $37,000 after buying an additional 11,406 shares during the period. HighTower Advisors LLC bought a new position in Fractyl Health during the third quarter worth about $38,000. Beta Wealth Group Inc. acquired a new position in shares of Fractyl Health during the 3rd quarter worth about $44,000. Finally, Stoneridge Investment Partners LLC bought a new stake in shares of Fractyl Health in the 4th quarter valued at about $45,000.

Wall Street Analyst Weigh In

Separately, Morgan Stanley reduced their price objective on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd.

Fractyl Health Price Performance

Shares of GUTS stock opened at $1.56 on Tuesday. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. Fractyl Health, Inc. has a 12-month low of $1.37 and a 12-month high of $10.50. The firm has a fifty day moving average of $1.77 and a 200-day moving average of $2.28. The firm has a market capitalization of $75.03 million and a price-to-earnings ratio of -0.13.

Fractyl Health (NASDAQ:GUTS) last posted its earnings results on Monday, March 3rd. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08). On average, equities research analysts forecast that Fractyl Health, Inc. will post -1.61 earnings per share for the current year.

Insider Activity at Fractyl Health

In other Fractyl Health news, CEO Harith Rajagopalan sold 90,972 shares of Fractyl Health stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $1.82, for a total value of $165,569.04. Following the transaction, the chief executive officer now owns 491,329 shares of the company’s stock, valued at approximately $894,218.78. The trade was a 15.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jay David Caplan sold 22,346 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $1.81, for a total transaction of $40,446.26. Following the completion of the transaction, the insider now owns 153,544 shares of the company’s stock, valued at $277,914.64. This trade represents a 12.70 % decrease in their position. The disclosure for this sale can be found here.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.